The symptom phenotype of oncology outpatients remains relatively stable from prior to through one week following chemotherapy
Files in This Item:
|The symptom phenotype of oncology outpatients remains from prior to one week following chemo post peer review.pdf||776.54 kB||Adobe PDF||Download|
|Title:||The symptom phenotype of oncology outpatients remains relatively stable from prior to through one week following chemotherapy||Authors:||Miakowski, Christine
Cooper, Bruce A.
Fox, Patricia A.
|Permanent link:||http://hdl.handle.net/10197/9007||Date:||May-2017||Abstract:||Some oncology outpatients experience a higher number of and more severe symptoms during chemotherapy (CTX). However, little is known about whether this high risk phenotype persists over time. Latent transition analysis (LTA) was used to examine the probability that patients remained in the same symptom class when assessed prior to the administration of and following their next dose of CTX. For the patients whose class membership remained consistent, differences in demographic and clinical characteristics, and quality of life (QOL) were evaluated. The Memorial Symptom Assessment Scale (MSAS) was used to evaluate symptom burden. LTA was used to identify subgroups of patients with distinct symptom experiences based on the occurrence of the MSAS symptoms. Of the 906 patients evaluated, 83.9% were classified in the same symptom occurrence class at both assessments. Of these 760 patients, 25.0% were classified as Low-Low, 44.1% as Moderate-Moderate and 30.9% as High-High. Compared to the Low-Low class, the other two classes were younger, more likely to be women and to report child care responsibilities, and had a lower functional status and a higher comorbidity scores. The two higher classes reported lower QOL scores. The use of LTA could assist clinicians to identify higher risk patients and initiate more aggressive interventions.||Funding Details:||European Commission - Seventh Framework Programme (FP7)||Type of material:||Journal Article||Publisher:||Wiley||Keywords:||Cancer;Chemotherapy;Latent transition analysis;Predictive risk modelling;Quality of life;Symptoms||DOI:||10.1111/ecc.12437||Language:||en||Status of Item:||Peer reviewed|
|Appears in Collections:||Nursing, Midwifery & Health Systems Research Collection|
Show full item record
This item is available under the Attribution-NonCommercial-NoDerivs 3.0 Ireland. No item may be reproduced for commercial purposes. For other possible restrictions on use please refer to the publisher's URL where this is made available, or to notes contained in the item itself. Other terms may apply.